The role of angiogenesis in the transformation of plexiform neurofibroma into malignant peripheral nerve sheath tumors in children with neurofibromatosis type 1

Journal of Pediatric Hematology/Oncology

Volumn 32, Issue 7, 2010, Pages 548-553

  Gesundheit, Benjamin ^a,b   Parkin, Patricia ^c   Greenberg, Mark ^b   Baruchel, Sylvain ^b   Senger, Christof ^c   Kapelushnik, Josef ^c   Smith, Charles ^c   Klement, Giannoula Lakka ^d  

^a International Center for Cell Therapy and Cancer Immunotherapy   (Israel)

^b Department of Pediatric Hematology and Oncology ^*  (Israel)

^c HOSPITAL FOR SICK CHILDREN   (Canada)

^d TUFTS MEDICAL CENTER   (United States)

Author keywords

smooth muscle actin ( SMA); Angiogenesis; Neurofibromatosis; Vascular endothelial growth factor (VEGF); Vascular endothelial growth factor receptor 1 (VEGFR 1); Vascular endothelial growth factor receptor 2 (VEGFR 2)

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2; VON WILLEBRAND FACTOR; ACTIN; FLT1 PROTEIN, HUMAN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ARTICLE; CHILD; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MALIGNANT TRANSFORMATION; NEUROFIBROMA; NEUROFIBROMATOSIS; PERIPHERAL NERVE TUMOR; PRESCHOOL CHILD; PRIORITY JOURNAL; VASCULARIZATION; ADOLESCENT; CELL TRANSFORMATION; HEALTH CARE FACILITY; METABOLISM; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); NERVE SHEATH TUMOR; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ACTINS; ADOLESCENT; CELL TRANSFORMATION, NEOPLASTIC; CHILD; FEMALE; HUMANS; MALE; MICROCIRCULATION; NEOVASCULARIZATION, PATHOLOGIC; NERVE SHEATH NEOPLASMS; NEUROFIBROMA, PLEXIFORM; NEUROFIBROMATOSIS 1; TISSUE BANKS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; VON WILLEBRAND FACTOR;

EID: 77958177947     PISSN: 10774114     EISSN: 15363678     Source Type: Journal    
DOI: 10.1097/MPH.0b013e3181e887c7     Document Type: Article

References (50)

1. Von Recklinghausen F. Ueber Die Miltiplen Fibrome der Haut und Ihre Beziehung zu den Multiplen Neuronen. Berlin: Hirschwald; 1882.
2. Matsui I, Tanimura M, Kobayashi N, et al. Neurofibromatosis type 1 and childhood cancer. Cancer. 1993;72:2746-2754.
3. American Academy of Pediatrics Commitee on Genetics. Health supervision for children with neurofibromatosis. Pediatrics. 1995;96:368-372.
4. Korf BR. Malignancy in neurofibromatosis type 1. Oncologist. 2000;5:477-485.
5. Korf BR. Neurocutaneous syndromes: neurofibromatosis 1, neurofibromatosis 2, and tuberous sclerosis. Curr Opin Neurol. 1997;10:131-136.
6. Gutmann DH, Aylsworth A, Carey JC, et al. The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. JAMA. 1997;278:51-57.
7. Mulvihill JJ, Parry DM, Sherman JL, et al. NIH conference. Neurofibromatosis 1 (Recklinghausen disease) and neurofibromatosis 2 (bilateral acoustic neurofibromatosis). An update. Ann Intern Med. 1990;113:39-52.
8. Zvulunov A, Barak Y, Metzker A. Juvenile xanthogranuloma, neurofibromatosis, and juvenile chronic myelogenous leukemia. World statistical analysis. Arch Dermatol. 1995;131:904-908.
9. Zachos M, Parkin PC, Babyn PS, et al. Neurofibromatosis type 1 vasculopathy associated with lower limb hypoplasia. Pediatrics. 1997;100:395-398.
10. Szudek J, Birch P, Riccardi VM, et al. Associations of clinical features in neurofibromatosis 1 (NF1). Genet Epidemiol. 2000;19:429-439.
11. Korf BR. Diagnosis and management of neurofibromatosis type 1. Curr Neurol Neurosci Rep. 2001;1:162-167.
12. Cutting LE, Koth CW, Denckla MB. How children with neurofibromatosis type 1 differ from "typical" learning disabled clinic attenders: nonverbal learning disabilities revisited. Dev Neuropsychol. 2000;17:29-47.
13. Listernick R, Louis DN, Packer RJ, et al. Optic pathway gliomas in children with neurofibromatosis 1: consensus statement from the NF1 optic pathway glioma task force. Ann Neurol. 1997;41:143-149.
14. Bader JL, Miller RW. Neurofibromatosis and childhood leukemia. J Pediatr. 1978;92:925-929.
15. Hope DG, Mulvihill JJ. Malignancy in neurofibromatosis. Adv Neurol. 1981;29:33-56.
16. Kimura N, Watanabe T, Fukase M, et al. Neurofibromin and NF1 gene analysis in composite pheochromocytoma and tumors associated with von Recklinghausens disease. Mod Pathol. 2002;15:183-188.
17. Schneider M, Obringer AC, Zackai E, et al. Childhood neurofibromatosis: risk factors for malignant disease. Cancer Genet Cytogenet. 1986;21:347-354.
18. Obringer AC, Meadows AT, Zackai EH. The diagnosis of neurofibromatosis-1 in the child under the age of 6 years. Am J Dis Child. 1989;143:717-719.
19. Coleman BG, Arger PH, Dalinka MK, et al. CT of sarcomatous degeneration in neurofibromatosis. AJR Am J Roentgenol. 1983;140:383-387.
20. Raney B, Schnaufer L, Ziegler M, et al. Treatment of children with neurogenic sarcoma. Experience at the childrens hospital of Philadelphia, 1958-1984. Cancer. 1987;59:1-5.
21. Angelov L, Davis A, OSullivan B, et al. Neurogenic sarcomas: experience at the university of Toronto. Neurosurgery. 1998; 43:56-64.
22. Korf BR. Plexiform neurofibromas. Am J Med Genet. 1999; 89:31-37.
23. Packer RJ, Prados M, Phillips P, et al. Treatment of children with newly diagnosed brain stem gliomas with intravenous recombinant beta-interferon and hyperfractionated radiation therapy: a childrens cancer group phase I/II study. Cancer. 1996;77:2150-2156.
24. Needle MN, Packer RJ. A phase II randomized trial of 13-cis retinoic acid (CRA) and Interferon alpha-2a in the treatment of PNF in patients with NF1. Pediatr Res. 1995;37:889. Abstract
25. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
26. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer. 1996;32A:2534-2539.
27. Folkman J. Fighting cancer by attacking its blood supply. Sci Am. 1996;275:150-154.
28. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996;86:353-364.
29. Rak J, Mitsuhashi Y, Bayko L, et al. Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. Cancer Res. 1995;55: 4575-4580.
30. Rak J, Filmus J, Finkenzeller G, et al. Oncogenes as inducers of tumor angiogenesis. Cancer Metastasis Rev. 1995;14:263-277.
31. Folkman J. Angiogenesis and angiogenesis inhibition: an overview. EXS. 1997;79:1-8.
32. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells1. Cell. 1998;94: 715-725.
33. Nguyen M, Watanabe H, Budson AE, et al. Elevated levels of an angiogenic peptide, basic fibroblast growth factor, in the urine of patients with a wide spectrum of cancers. J Natl Cancer Inst. 1994;86:356-361.
34. Ezekowitz RA, Mulliken JB, Folkman J. Interferon alfa-2a therapy for life-threatening hemangiomas of infancy. N Engl J Med. 1992;326:1456-1463.
35. Marler JJ, Rubin JB, Trede NS, et al. Successful antiangiogenic therapy of giant cell angioblastoma with interferon alfa 2b: report of 2 cases. Pediatrics. 2002;109:E37.
36. Dinney CP, Bielenberg DR, Perrotte P, et al. Inhibition of basic fibroblast growth factor expression, angiogenesis, and growth of human bladder carcinoma in mice by systemic interferon-alpha administration2. Cancer Res. 1998;58:808-814.
37. Angelov L, Salhia B, Roncari L, et al. Inhibition of angiogenesis by blocking activation of the vascular endothelial growth factor receptor 2 leads to decreased growth of neurogenic sarcomas. Cancer Res. 1999;59:5536-5541.
38. Kawachi Y, Xu X, Ichikawa E, et al. Expression of angiogenic factors in neurofibromas. Exp Dermatol. 2003;12:412-417.
39. Kurtz A, Martuza RL. Antiangiogenesis in neurofibromatosis.J Child Neurol. 2002;17:578-584.
40. Mashour GA, Ratner N, Khan GA, et al. The angiogenic factor midkine is aberrantly expressed in NF1-deficient Schwann cells and is a mitogen for neurofibroma-derived cells. Oncogene. 2001;20:97-105.
41. Gupta A, Cohen BH, Ruggieri P, et al. Phase I study of thalidomide for the treatment of plexiform neurofibroma in neurofibromatosis 1. Neurology. 2003;60:130-132.
42. Benjamin LE, Golijanin D, Itin A, et al. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J Clin Invest. 1999;103:159-165.
43. Pettersson A, Nagy JA, Brown LF, et al. Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000;80:99-115.
44. Auerbach R, Auerbach W, Polakowski I. Assays for angiogenesis: a review. Pharmacol Ther. 1991;51:1-11.
45. Jain RK, Schlenger K, Hockel M, et al. Quantitative angio genesis assays: progress and problems. Nat Med. 1997;3: 1203-1208.
46. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesnt tell us. J Natl Cancer Inst. 2002;94:883-893.
47. Teixeira F, Martinez-Palomo A, Riccardi VM, et al. Vascular changes in cutaneous neurofibromas. Neurofibromatosis. 1988;1:5-16.
48. Zhu Y, Ghosh P, Charnay P, et al. Neurofibromas in NF1: Schwann cell origin and role of tumor environment. Science. 2002;296:920-922.
49. Gitler AD, Zhu Y, Ismat FA, et al. Nf1 has an essential role in endothelial cells. Nat Genet. 2003;33:75-79.
50. Mashour GA, Wang HL, Cabal-Manzano R, et al. Aberrant cutaneous expression of the angiogenic factor midkine is associated with neurofibromatosis type-1. J Invest Dermatol. 1999;113:398-402.